Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2023-11-13 Major Shareholding Noti…
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2023-11-13 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, reporting the financial results for the quarter ended September 30, 2023. It includes a press release announcing quarterly financial results and a corporate update. The document explicitly states it is a Current Report on Form 8-K and includes a press release as an exhibit. The content corresponds to an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). The document length is 3740 characters, which is typical for an earnings release announcement rather than a full interim report. Therefore, the correct classification is Earnings Release (ER).
2023-11-09 English
4
Director's Dealing
2023-11-08 English
Regulatory Filings 2023
Regulatory Filings
2023-11-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates that shareholders should know about. The text includes announcements about upcoming presentations at a medical conference, updates on clinical trials, and a scheduled conference call. It also includes a press release and abstracts as exhibits. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document is not a transcript, audit report, or governance information. It is primarily an announcement of operational updates and upcoming events, consistent with a Regulatory Filing (RNS) as a catch-all category for miscellaneous filings that do not fit other specific categories. The document length (10,406 characters) and content support this classification rather than a full report or earnings release.
2023-11-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.